Last Updated on September 20, 2021 by The Health Master
Zydus Cadila has received final approval from the USFDA to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets). Vortioxetine is used to treat depression.
It works by helping to restore the balance of a certain natural substance (serotonin) in the brain.
Vortioxetine is an SSRI (selective serotonin reuptake inhibitor) and serotonin receptor modulator.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 322 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila gets tentative nod from USFDA for Brexpiprazole tablets
USFDA to review use of Blood Disorder Therapy in children
Aleor gets USFDA final approval for Metronidazole gel
Dr Reddy’s Labs gets USFDA nod for generic Librax capsules
Granules India gets Health Canada nod for drug for Arthritis pain
Sun Pharma gets exclusive right for Winlevi acne cream in US,…
Illegal Blood supply racket busted
Amoxycillin: Investigation of Anti Dumping duty
Proposed 12% GST on APIs not to benefit Bulk Drug Manufacturers
Nutraceuticals: A strong Regulation is needed
India and Pharmacy Education: Chapter: 7
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon: